Q-omics provides the consensus-scored GANC profile across patient tissues and cancer cell-line models. GANC expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GANC is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, GANC RNA expression shows 20,987 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, LUAD, and UVM as cancer lineages where GANC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GANC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GANC survival associations across molecular data types. GANC RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GANC RNA expression–survival associations across cancer types. High GANC expression shows unfavorable associations in KICH, UVM and ACC, but favorable associations in LUAD, KIRP and MESO. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for GANC RNA expression.
This table summarizes GANC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for GANC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GANC shows lower tumor expression in LUAD, LUSC, KICH and BRCA and higher tumor expression in HNSC and LIHC. The LUAD box plot shows higher GANC RNA expression in normal versus tumor tissue (log2 FC = −1.083, t-test p < 0.001).
This table shows molecular features associated with GANC in patient tissues and cancer cell lines. In patient samples, GANC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GANC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Lymphoma.
